Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 8NIH 3INDUSTRY 2OTHER_GOV 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Neoplasms 3214Carcinoma, Non-Small-Cell Lung 2727Breast Neoplasms 2550Colorectal Neoplasms 1461Prostatic Neoplasms 1307Neoplasm Metastasis 1300Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 944Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 832Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 472Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 435Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Cystadenocarcinoma, Serous × Clear all
NCT05949632 2026-06-04

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Incyte Corporation

Phase 1/2 Terminated
5 enrolled 13 charts
GynecologicSarcoma

Adenocarcinoma, Mucinous, Carcinosarcoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Cystadenocarcinoma, Serous

NCT04814108 2026-03-18

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 2 Completed
92 enrolled

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡